http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2018538263-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-33 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-507 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate | 2016-11-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2018-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2018538263-A |
| titleOfInvention | Method for treating lung cancer using a combination of anti-PD-1 antibody and anti-CTLA-4 antibody |
| abstract | The present invention provides a method for treating a subject suffering from lung cancer, wherein the method is specific for a therapeutically effective amount of (a) programmed cell death-1 (PD-1) receptor. An antibody or antigen-binding portion thereof that binds to and inhibits PD-1 activity; and (b) specifically binds to cytotoxic T lymphocyte antigen-4 (CTLA-4) and inhibits CTLA-4 activity Administering to the subject an antibody or antigen binding portion thereof. |
| priorityDate | 2015-11-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 245.